Jump to content

10,11-Seco-LSD

Edit links
From Wikipedia, the free encyclopedia

10,11-Seco-LSD
Clinical data
Other namesUCD0121; "[0124]"; 9,10-Didehydro-N,N-diethyl-6-methyl-10,11-secoergoline-8β-carboxamide
Drug classPartial ergoline
ATC code
  • None
Identifiers
CAS Number
Chemical and physical data
3D model (JSmol)
  • O=C([C@@]1C=C[C@@]([H])(CC2=CN([H])C3=CC=CC=C23)N(C)C1)N(CC)CC
  • InChI=1S/C20H26N3O/c1-4-23(5-2)20(24)15-10-11-17(22(3)14-15)12-16-13-21-19-9-7-6-8-18(16)19/h6-11,13,17,21H,4-5,12,14H2,1-3H3/t17-/m0/s1
  • Key:CGFPZODXTFFRAH-KRWDZBQOSA-N

10,11-Seco-LSD, also known as UCD0121, is a partial lysergamide and cyclized tryptamine related to lysergic acid diethylamide (LSD).[1][2] It is the seco analogue of LSD in which the bond between the 10 and 11 positions of the ergoline ring system has been broken.[1][2] 10,11-Seco-LSD was described in a patent by David E. Olson and colleagues at Delix Therapeutics in 2021.[2] Subsequently, 10,11-seco-LSD was further described by Olson and colleagues in the scientific literature in 2026.[1]

LSD (left) and 10,11-seco-LSD (right) chemical structures.

See also

[edit]

References

[edit]
  1. 1 2 3 Basargin AG, Domokosa A, Hennessey JJ, Aarrestad IK, Sambyal R, Khatib YA, et al. (September 2026). "Deconstruction of lysergic acid diethylamide". Proc Natl Acad Sci U S A. 123 (38) e2603412123. doi:10.1073/pnas.2603412123. PMID 42709856.
  2. 1 2 3 WO 2021076572, Olson DE, Dunlap LM, Wagner F, Chytil M, Powell NE, "Ergoline-like compounds for promoting neural plasticity", published 22 April 2021, assigned to Delix Therapeutics, Inc. and The Regents of the University of California
Retrieved from "https://en.wikipedia.org/w/index.php?title=10,11-Seco-LSD&oldid=1377214790"